Skip to content

Biomarker-guided Implementation of the AKI Bundle

Biomarker-guided Implementation of the Cardiovascular (CV) Surgery AKI Bundle to Reduce the Occurrence of AKI After Cardiac Surgery- Prevention of AKI

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03244514
Acronym
PrevAKI-mc
Enrollment
280
Registered
2017-08-09
Start date
2017-11-02
Completion date
2020-01-26
Last updated
2020-02-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Kidney Injury (Nontraumatic)

Keywords

cardiac surgery, KDIGO-Guideline

Brief summary

There is no specific therapy for acute kidney injury. It is presumed that supportive measures improve the care and outcome of patients with acute kidney injury. The investigators hypothesize that the implementation of a bundle of supportive measures adapted to patients undergoing cardiovascular surgery reduces the occurence of AKI. A Randomized prospective multicenter trial is needed to investigate whether the implementation of the bundle of measures is effective to prevent AKI in high risk patients undergoing cardiac surgery. In this feasibility trial the investigators will analyze the compliance rate to the trial protocol in a multicenter, multinational cohort in preparation for a large randomized controlled trial.

Interventions

OTHERIntervention

Implementation of the cardiovascular AKI bundle (see arm description)

Sponsors

European Society of Intensive Care Medicine
CollaboratorOTHER
University Hospital Muenster
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Adult patients undergoing cardiac surgery with cardiopulmonary bypass (CPB) * Urinary \[TIMP-2\] \* \[IGFBP7\] \>= 0.3 4h after CPB * Written informed consent

Exclusion criteria

* Preexisting AKI (stage 1 and higher) * Patients with cardiac assist devices (ECMO, LVAD, RVAD, IABP) * Pregnancy, breastfeeding * Known (Glomerulo-)-Nephritis, intersstitial nephritis or vasculitis * CKD with eGFR \< 20 mL/min * Dialyses dependent CKD * Prior kidney transplant within the last 12 months

Design outcomes

Primary

MeasureTime frameDescription
Compliance rate48 hours after start of interventionproportion of patients who are treated according to the trial protocol: CV surgery AKI bundle fulfilled at all time

Secondary

MeasureTime frameDescription
Moderate and severe AKI72 hours after start of intervention
Free-days through of vasoactive medications and mechanical ventilation28 days after start of intervention
Renal recovery90 days after start of interventionrenal recovery is defined as serum creatinine levels \< 0.5 mg/dl higher than baseline serum creatinine (creatinine level before surgery)
Occurence of AKI72 hours after start of intervention
ICU and hospital stayup to 1 year after start of intervention (until discharge)
Number of patients with renal replacement therapy90 days after start of intervention
Mortality90 days after start of intervention

Countries

Belgium, Germany, Italy, Spain, United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 18, 2026